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Abstract
Background: The World Health Organization endorses the use of artemisinin-based combination therapy for
treatment of acute uncomplicated falciparum malaria in the second and third trimesters of pregnancy. However,
the effects of pregnancy on the pharmacokinetics of artemisinin derivatives, such as artesunate (AS), are poorly
understood. In this analysis, the population pharmacokinetics of oral AS, and its active metabolite
dihydroartemisinin (DHA), were studied in pregnant and non-pregnant women at the Kingasani Maternity Clinic in
the DRC.
Methods: Data were obtained from 26 pregnant women in the second (22 - 26 weeks) or the third (32 - 36
weeks) trimester of pregnancy and from 25 non-pregnant female controls. All subjects received 200 mg AS. Plasma
AS and DHA were measured using a validated LC-MS method. Estimates for pharmacokinetic and variability
parameters were obtained through nonlinear mixed effects modelling.
Results: A simultaneous parent-metabolite model was developed consisting of mixed zero-order, lagged first-order
absorption of AS, a one-compartment model for AS, and a one-compartment model for DHA. Complete
conversion of AS to DHA was assumed. The model displayed satisfactory goodness-of-fit, stability, and predictive
ability. Apparent clearance (CL/F) and volume of distribution (V/F) estimates, with 95% bootstrap confidence
intervals, were as follows: 195 L (139-285 L) for AS V/F, 895 L/h (788-1045 L/h) for AS CL/F, 91.4 L (78.5-109 L) for
DHA V/F, and 64.0 L/h (55.1-75.2 L/h) for DHA CL/F. The effect of pregnancy on DHA CL/F was determined to be
significant, with a pregnancy-associated increase in DHA CL/F of 42.3% (19.7 - 72.3%).
Conclusions: In this analysis, pharmacokinetic modelling suggests that pregnant women have accelerated DHA
clearance compared to non-pregnant women receiving orally administered AS. These findings, in conjunction with
a previous non-compartmental analysis of the modelled data, provide further evidence that higher AS doses would
be required to maintain similar DHA levels in pregnant women as achieved in non-pregnant controls.
Background
Infection with Plasmodium falciparum during pregnancy
can have severe health consequences for both the
infected woman and her unborn child. In regions of
unstable malaria transmission, in which acquired immu-
nity to malaria is minimal, pregnant women are more
vulnerable to severe falciparum malaria infection. In
areas of stable malaria transmission, including most of
sub-Saharan Africa, pregnant women experience higher
rates of falciparum parasitaemia and severe malaria-
related anaemia than their non-pregnant counterparts
[1]. In these regions, placental malaria infection, charac-
terized by P. falciparum sequestration in placental tis-
sue, also represents a significant public health threat.
Placental malaria, particularly when paired with mater-
nal anaemia, can compromise foetal nutrition, resulting
* Correspondence: l-fleckenstein@uiowa.edu
1University of Iowa, College of Pharmacy, 115 South Grand Avenue, Iowa
City, IA 52242, USA
Full list of author information is available at the end of the article
Morris et al. Malaria Journal 2011, 10:114
http://www.malariajournal.com/content/10/1/114
© 2011 Morris et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
in intrauterine growth restriction, preterm birth, and
low birth weights [1]. In sub-Saharan Africa, malaria
infection in pregnancy is responsible for an estimated
20% of low birth weight deliveries and a consequent
100,000 infant deaths every year [2].
The World Health Organization (WHO) recommends
artemisinin-based combination therapy (ACT) as a first-
line treatment for acute, uncomplicated falciparum
malaria in the second and third trimesters of pregnancy
[3]. Additionally, the inclusion of artemisinin derivatives
in novel intermittent preventative treatment regimens
for pregnant women has been proposed as a means to
combat the effects of increasing resistance to the cur-
rently used agent, sulphadoxine-pyrimethamine (SP) [4].
Despite the current and potential applications of arte-
misinin derivatives to the treatment and prevention of
malaria in pregnant women, understanding of how the
physiologic changes of pregnancy may alter the pharma-
cokinetics, and therefore potentially the efficacy, of arte-
misinin derivatives is relatively limited. To date, only
three published analyses regarding the pharmacokinetics
of such derivatives in pregnant women are available.
Two were conducted by McGready and colleagues, who
assessed the pharmacokinetics of artesunate (AS) and
artemether in Thai women in the second and third tri-
mesters of pregnancy with acute uncomplicated falci-
parum malaria [5,6]. Their findings suggest that in
pregnant women, exposure to dihydroartemisinin
(DHA), the common active metabolite of AS and arte-
mether, is substantially lower than exposure reported in
previous studies with non-pregnant adults. In a recent
non-compartmental pharmacokinetic study, the clear-
ance of DHA was determined to be faster in pregnant
women than non-pregnant controls, but not than in the
same women three months postpartum [7].
To date, no population pharmacokinetic analysis of an
artemisinin derivative has been conducted utilizing data
from not only pregnant subjects, but also non-pregnant
controls. The objective of this analysis was to utilize a
population pharmacokinetic approach to model the
pharmacokinetics of oral AS, a water soluble artemisinin
derivative, and its active metabolite DHA, in pregnant
women and controls and to identify clinically relevant
covariates associated with inter-individual variability in
AS and DHA pharmacokinetics.
Methods
Study design
The clinical aspects of this single center, open label
study (Clinicaltrials.gov: NCT00538382) were con-
ducted at the Kingasani Maternity Clinic in Kinshasa,
Democratic Republic of Congo (DRC). Women pre-
senting for prenatal care at the clinic were screened
for study eligibility if they were between 18 and 40
years of age and at less than 22 weeks gestation, deter-
mined by last menstrual period. Women confirmed by
ultrasound to be between 8 to 21 weeks gestation
(inclusive) were invited to be participants in the study.
Women were asked to return between 22 to 26 weeks
gestation for screening and enrollment; women not
enrolled at 22 to 26 weeks were screened again at 32
to 36 weeks gestation. A cohort of non-pregnant
female controls was also enrolled. At the time of
enrollment, both the pregnant and non-pregnant sub-
jects had asymptomatic Plasmodium falciparum parasi-
taemia, with a parasite density between 200 and
300,000 parasite/μL, were HIV seronegative, and were
without anaemia (haematocrit >30%) or other major
medical problems (e.g. chronic hypertension, diabetes,
etc.). Plasmodium falciparum parasite density was
assessed though Giemsa staining of thick and thin
blood films; slide-positive infections were later PCR-
confirmed using DNA extracted from dried blood
spots [8]. The study protocol was approved by the
ethical committees of the University of North Carolina
at Chapel Hill, the Kinshasa School of Public Health,
and the Research Triangle Institute. The study was
carried out in accordance with the Helsinki Declara-
tion. Only women able to understand the study proto-
col and who gave informed consent were enrolled in
the study. Further details of the clinical and safety
aspects of this trial, including additional biochemical
assessments, are described by Onyamboko et al [7].
For pregnant subjects, pharmacokinetic studies were
conducted both at the time of enrollment, as well as at
three months postpartum. All subjects received 200
mg oral AS, administered as four 50 mg tablets (Guilin
Pharmaceutical Co. Ltd) at the beginning of an inpati-
ent stay at the clinic. Blood samples (5 mL) for phar-
macokinetic analysis were drawn at pre-dose and at
0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, and 8 hours after AS
administration. Twenty-four hours following AS
administration, malaria-infected women received 1725
mg SP to complete treatment. Blood sampling schedule
and sample handling were uniformly applied for preg-
nant, postpartum, and control subjects. Blood samples
were collected in pre-chilled tubes containing potas-
sium oxalate/sodium fluoride. Following collection,
tubes were placed on wet ice; within 5 minutes of col-
lection, samples were centrifuged. Immediately follow-
ing centrifugation, plasma was removed from the cells
and transferred into cryovials. The plasma samples
were transferred to liquid nitrogen until they could be
frozen at or below -80°C in a laboratory freezer; sam-
ples were later shipped on dry ice to the Clinical Phar-
macokinetics Laboratory at the College of Pharmacy,
University of Iowa, where they were stored at -80°C
until drug analysis was performed.
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Sample analysis
Determination of AS and DHA plasma concentrations
was performed using a validated liquid chromatography-
mass spectrometric method described by Naik et al [9]
with minor modifications to allow for extraction from a
smaller plasma volume. Briefly, solid phase extraction
was used to extract AS, DHA, and the internal standard
artemisinin from 0.25 mL of human plasma. The recon-
stituted extracts were chromatographed isocratically.
Mass spectroscopy in positive ion mode was used to
detect and quantify the compounds. The lower limit of
quantification (LLQ) for both AS and DHA was 1 ng/
mL. Assay validation indicated that assay precision was
5.8 - 8.6% (coefficient of variation) for AS and 6.5 -
8.2% for DHA.
Population pharmacokinetic analysis
Nonlinear mixed effects model building was conducted
using NONMEM software version 7 (ICON Develop-
ment Solutions, Ellicott City, MD) [10] implemented on
a Windows XP operating system (Microsoft Corpora-
tion, Seattle, WA) with a G95 Fortran compiler (Free
Software Foundation, Boston, MA). Monte Carlo impor-
tance sampling expectation maximization with interac-
tion (IMP INTER) estimation method was used to fit
models. Pdx-Pop 4.0 (ICON Development Solutions,
Ellicott City, MD) and Xpose version 4.1.0 (Uppsala
University, Uppsala, Sweden) [11] were used in proces-
sing NONMEM 7 output. Plots were generated with
TIBCO Spotfire S+ version 8.1 (TIBCO Software Inc.,
Palo Alto, CA) and R version 2.10.0 (Free Software
Foundation, Boston, MA).
Model selection was guided by the following criteria:
plausibility and precision of parameter estimates, mini-
mum objective function value (MOFV), equal to minus
twice the log likelihood function, Akaike Information
Criterion, equal to MOFV plus two times the number of
parameters, condition number, equal to the ratio of the
largest Eigen value to the smallest Eigen value, and
inspection of diagnostic plots.
Prior to modelling, AS and DHA concentrations were
converted from ng/mL to nmol/L values using the com-
pounds’ respective molecular weights; the concentra-
tions were then natural log-transformed. The 200 mg
AS dose was similarly converted to the appropriate
value in nmols.
Modelling was initially conducted with an aggregate
data set of pregnancy, postpartum, and control observa-
tions. A structural model adequately describing data
from all three groups could not be identified. As this
difficulty appeared to stem from the erratic and unpre-
dictable AS and DHA observations from the postpartum
subjects, the data were subsequently divided into preg-
nancy/control and postpartum data sets for structural
model identification. Since an adequate structural model
could only be identified for the pregnancy/control data
set, the Base model development and Covariate model
building sections that follow describe model building
using the pregnancy/control data set, with details
regarding attempts to model postpartum data provided
in Results.
Base model development
Modelling was first performed with AS data only; first-
order absorption with one-compartment and two-com-
partment models were fitted to these data. Alternative
absorption processes were also assessed, including first-
order absorption, zero-order absorption with lagged
first-order absorption, first-order absorption with lagged
zero-order absorption, parallel dual first-order absorp-
tion, single Weibull absorption, and transit compart-
ment absorption. DHA data were also initially modelled
independently in order to determine if a one- or two-
compartment model better characterized observed
concentrations.
Multiple simultaneous parent-metabolite models con-
sisting of a one-compartment model for AS and a one-
compartment model for DHA with various AS absorp-
tion types were assessed. These simultaneous models
included the absorption processes assessed with AS data
only, as well as parallel dual first-order absorption of
both AS and DHA from a gut compartment. Complete,
irreversible conversion of AS to DHA was assumed for
all models [12]. Simultaneous models were implemented
using ADVAN 5.
Inter-individual variability (IIV) was modelled on
pharmacokinetic parameters using a log-normal distri-
bution:
Pi = Ppop · exp(ηi)
where Pi represents the parameter estimate for indivi-
dual i, Ppop represents the population estimate for the
parameter, and hi represents the deviation of Pi from
Ppop..
Residual variability (RV) was modelled with an addi-
tive model for log-transformed data:
ln Cij = ln Cpred, ij + εij
where Cij represents the jth observation for individual
i, Cpred, ij represents the predicted AS or DHA concen-
tration for individual i, and εij represents the residual
random error for the jth observation of individual i.
Covariate model building
Once the optimal base model was determined, covariate
analysis was undertaken to identify any covariates
explaining a significant portion of the observed IIV.
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Covariates examined included age, weight, body mass
index (BMI), baseline alpha-1-acid glycoprotein (AGP),
baseline albumin, pregnancy status, and window of preg-
nancy. Examined covariates represented available demo-
graphic and clinical variables which could plausibly alter
AS or DHA pharmacokinetics. Potential covariate-para-
meter relationships were identified by examining plots
of covariates versus parameter estimates and covariates
versus IIV. Covariate screening was also conducted
using generalized additive modelling in Xpose software.
Physiologically plausible covariate-parameter relation-
ships suggested by evaluation of covariate plots and/or
by generalized additive modelling were evaluated for sta-
tistical significance using a process of forward addition
and backward elimination [13]. The statistical criteria
for a covariate to be retained in the model during for-
ward addition was p < 0.05; for backward elimination,
the criteria was p < 0.001.
Categorical covariates were modelled using a propor-
tional function:
P = θ1 · (1 + θ2 · COV)
where θ1 represents the parameter estimate in subjects
with the covariate coded as 0 and θ2 represents the
change in the parameter associated with the categorical
covariate being tested.
Continuous covariates were centered on their median
and modelled using a linear function:
P = θ1 +θ2 · (COV− COVmedian)
where θ1 represents the parameter estimate for an
individual with COV equal to COVmedian, and θ2 repre-
sents the change in the parameter estimate associated
with the difference between COV from COVmedian.
Model evaluation
Diagnostic plots used to assess model goodness-of-fit
included observed concentrations versus population
predictions, observed concentrations versus individual
predictions, conditional weighted residuals (CWRES)
versus population predictions, and CWRES versus time.
Population predictions were obtained using the EPRED
option in NONMEM 7.
One thousand bootstrap runs were conducted using
Perl-Speaks-NONMEM version 3.1.0 [14] in order to
assess the precision of the parameter estimates. Model
stability was assessed by condition number, with a con-
dition number less than 1000 considered indicative of
model stability. The predictive ability of the model was
evaluated by simulating 1000 virtual observations for
each sampling time point. The observed concentrations
were plotted with the 5th, 50th, and 95th percentiles of
the simulated data above LLQ. The percent of observed
concentrations outside of the 90% prediction interval,
defined by the 5th and 95th percentiles, were computed
for both AS and DHA.
Results
Subject data
Demographic and clinical data for the pregnant women
and controls enrolled in this study are provided in Table
1. Thirteen pregnant women were enrolled in each of
the two windows of pregnancy. All pregnant (n = 26)
and control subjects (n = 25) were assessed as slide
positive and PCR-positive for falciparum parasitaemia at
enrollment, although at the time of AS administration,
typically occurring one day following enrollment, two
pregnant and 11 control subjects were assessed as slide
negative for parasitaemia. All infections were P. falci-
parum monoinfections with the exception of one preg-
nant woman with P. falciparum - P. malariae co-
infection. All previously pregnant subjects were lactating
at the time of postpartum evaluation. Only two postpar-
tum subjects were slide positive for parasitaemia, includ-
ing one subject with a mixed infection.
Of the collected samples for pregnancy and control
group patients, 41% of AS (40% pregnancy, 41% control)
Table 1 Summary of subject data for pregnant, postpartum, and non-pregnant women
Pregnancy Postpartum Controls
Age (years) 23 (19 - 35) 24 (20 - 36) 24 (18 - 38)
Weight (kg) 63 (40 - 71) 55 (39 - 67) 52 (42 - 84)
BMI (kg/m2) 23 (17 - 27) 22 (17 - 25) 21 (17 - 28)
Parasite density at enrollment† 528 (372 - 842) NA‡ 807 (325 - 2215)
Baseline ALT (Units/L) 15 (8 - 31) 21 (12 - 71) 18 (11 - 67)
Baseline AST (Units/L) 26 (19 - 43) 29 (17 - 64) 32 (19 - 46)
Baseline Albumin (g/dL) 2.6 (2.1 - 3.4) 3.3 (1.8 - 5.7) 3.3 (2.8 - 4.0)
Baseline AGP (mg/dL) 70 (43 - 123) 80 (32 - 162) 99 (62 - 177)
All values given as Median (Range) unless otherwise specified.
†Values given as median (interquartile range).
‡Only two women in the postpartum group were slide positive for malaria.
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and 2% of DHA observations (<1% pregnancy, 2% con-
trol) fell below LLQ and were excluded prior to model
building. One AS observation and one DHA observation
were identified as outliers and excluded from the analy-
sis. Modelling was conducted using 300 AS and 498
DHA concentrations.
Model development
When AS data were modelled independently using first-
order absorption, a two-compartment model did not
improve model fit as compared to a one-compartment
model. A two-compartment model was also not prefer-
able to a one-compartment model for DHA data. A
simultaneous parent-metabolite model with a one-com-
partment model for AS, a one-compartment model for
DHA, and mixed zero-order, lagged first-order absorp-
tion was associated with lower bias in goodness-of-fit
plots than simultaneous models with alternative AS
absorption processes. Use of mixed zero-order, lagged
first-order absorption was associated with a MOFV
reduction of 665 as compared to use of a first-order
absorption model.
The final base model, illustrated in Figure 1, was para-
meterized in terms of the duration of the zero-order
absorption process (D2), the rate constant of the lagged
first-order absorption process (K12), the fraction of the
dose absorbed by the first-order absorption process (F1),
the lag time for the first-order absorption process
(ALAG1), the apparent clearance of AS (CL/F), the
apparent clearance of DHA (CLM/F), the apparent
volume of distribution of AS (V2/F), and the apparent
volume of distribution of DHA (V3/F).
The following covariate relationships were assessed
during covariate modelling: pregnancy status on CLM/F,
CL/F, D2, and V3/F and weight on V2/F, CLM/F, and
V3/F. In the final model, only one covariate, pregnancy
status on clearance of DHA, was retained as significant
at the p < 0.001 level. Although not statistically signifi-
cant in the full covariate analysis, the effect of pregnancy
status on DHA volume of distribution was the only
tested covariate relationship, apart from pregnancy sta-
tus on CLM/F, that was significant (p < 0.05) in the first
forward addition step of covariate modelling. Pregnancy
was associated with a trend towards increased DHA
volume of distribution of approximately 37%.
The IIV values associated with CL/F and F1 were
fixed after conclusion of covariate model building due
to poor precision in omega estimates. NONMEM para-
meter estimates and relative standard errors are given in
Table 2. The final parameter estimates for the model
were used to generate the typical DHA concentration-
time profiles, plotted in Figure 2, for the pregnant and
non-pregnant women.
For postpartum data, the following absorption models,
with a one-compartment model for AS and a one-com-
partment model for DHA, were assessed: first-order
absorption, zero-order absorption, zero-order absorption
with lagged first-order absorption, first-order absorption
Figure 1 Diagram of final structural model for AS and DHA pharmacokinetics.
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with lagged zero-order absorption, parallel dual first
order absorption, single Weibull absorption, transit
compartment absorption, and absorption of both AS
and DHA from the gut. None of the structural models
assessed provided adequate predictive power for DHA
observations. Specifically, more than 20% of the DHA
concentrations fell outside the visual predictive check
90% prediction interval. Attempts to model only DHA
observations using various absorption processes were
similarly unsuccessful.
Model evaluation
Goodness-of-fit plots for AS and DHA are given in Fig-
ures 3 and 4, respectively. Mean parameter estimates
and percentile-based bootstrap 95% confidence intervals
obtained from 1000 bootstrap runs are given in Table 2.
Minimization was successful in 99.9% of bootstrap runs.
All parameter estimates from the final model fall within
the bootstrap confidence intervals. The condition num-
ber for the final model is 7.2, indicating good model sta-
bility. For the visual predictive check, 7.2% of AS and
11.2% of DHA observations fall outside the respective
AS and DHA 90% prediction intervals, suggesting that
the model has adequate predictive power. The visual
predictive check plots for AS and DHA are in Figure 5.
Discussion
In the present analysis, a population pharmacokinetic
model was developed for AS and its active metabolite
DHA using extensive sampling data from 26 pregnant
and 25 non-pregnant women in the DRC. The model
Table 2 Parameter estimates, standard error, and bootstrap confidence intervals for final model
Parameter Estimate %RSE Bootstrap mean (95% CI)
K12 (h-1) 4.28 23.6 4.43 (2.73-7.16)
D2 (h) 4.04 19.5 3.99 (2.37-6.27)
ALAG1 (h) 0.627 10.9 0.630 (0.494-0.771)
F1 0.864 1.56 0.867 (0.839-0.887)
CL/F (L/h) 895 5.9 904 (788-1045)
V2/F (L) 195 16.4 201 (139-285)
CLM/F (L/h) 64.0 6.53 64.2 (55.1-75.2)
V3/F (L) 91.4 6.15 92.1 (78.5-109)
PREG on CLM/F 0.423 30.3 0.427 (0.197-0.723)
IIV - Variances (%CV)
IIV - K12 1.84 (136) 25.3 1.76 (0.986-2.77)
IIV - D2 1.33 (115) 22.9 1.33 (0.64-2.15)
IIV - ALAG 0.573 (75.7) 20.8 0.581 (0.333-0.91)
IIV - V2/F 0.604 (77.7) 30.1 0.568 (0.253-0.942)
IIV - CLM/F 0.0802 (28.3) 24.9 0.0711 (0.031-0.113)
IIV - V3/F 0.0790 (28.1) 34.7 0.00661 (0.00591-0.139)
RV - Variances
AS 0.696 11.6 0.721 (0.515-0.971)
DHA 0.174 9.94 0.174 (0.129-0.226)
RSE: Relative standard error; K12: rate of first-order absorption process for AS; D2: duration of zero-order absorption process for AS; ALAG1: lag time for first-order
absorption process; F1: fraction of dose absorbed by the first-order process; CL/F: apparent clearance of AS; V2/F: apparent volume of distribution of AS; CLM/F:
apparent clearance of DHA; V3/F: apparent volume of distribution of DHA; PREG on CLM/F: factor of proportional increase in CLM/F associated with pregnancy;
IIV: Interindividual variability.
Figure 2 Typical DHA concentration-time profiles for pregnant
and non-pregnant women based on model parameter estimates.
The dashed line represents the typical profile for pregnant women.
The solid line represents the typical profile for non-pregnant women.
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consists of a one-compartment model for AS and a one-
compartment model for DHA, with AS absorption
occurring through a mixed zero-order, lagged first-order
absorption process. Upon absorption, AS is rapidly con-
verted to DHA, with an approximate AS elimination
half-life of 9.1 minutes. The model indicates that DHA
apparent clearance is approximately 42% higher in preg-
nant than non-pregnant subjects, with resultant DHA
elimination half-life estimates of 45 minutes and 59
minutes for pregnant and non-pregnant subjects,
respectively.
The rapid elimination of AS found in this analysis is
consistent with findings of pharmacokinetic analyses
with IV AS, with an AS half-life estimate of 13.2 min-
utes obtained by Newton et al [15] and estimates of less
than ten minutes found by Binh et al [16] and Batty et
al [17]. Given this rapid conversion of AS to DHA, the
rate of DHA formation may be limited by the rate of AS
absorption. The multiple samples collected in this study
during the early period following AS administration
allowed for AS absorption to be characterized using a
mixed zero-order, lagged first-order absorption process
that offered marked improvement in model fit over sim-
pler absorption models. Given that AS is a weak acid
with a pKa of 4.6 [18], absorption though this mixed-
order process may reflect AS solubility and permeability
changes occurring in the differing pH environments
encountered in gastrointestinal transit. Gastric absorp-
tion of AS may be limited by the solubility of the free
acid form of AS (168.2 μg/mL) [19]; such solubility-lim-
ited absorption would plausibly correspond to a zero-
order process [20] such as the process characterizing
the initial phase of AS absorption in the mixed-order
absorption model utilized in the present analysis.
Erratic AS absorption in the postpartum women
appears to have contributed substantially to the diffi-
culty in identifying a satisfactorily predictive structural
model for describing data from the postpartum sub-
jects. Given the rapid conversion of AS to DHA upon
AS absorption, unpredictable AS absorption would be
expected to produce a pattern of DHA appearance
inconsistent with standard compartmental modelling.
The source of this atypical absorption may relate
to breastfeeding; the women in the study were
Figure 3 Goodness-of-fit plots for AS. Dotted lines are smoothing lines. Solid lines are lines of identity.
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encouraged to bring their infants to the study site and
to feed the children prior to AS administration. The
effects of lactation on maternal kinetics have not been
extensively studied. However, some studies have been
performed evaluating the effects of lactation on ethanol
kinetics. These studies report changes in ethanol phar-
macokinetics, which may represent altered patterns of
ethanol absorption, associated with the lactational state
in general, as well as more acute effects induced by
breast pumping or, presumably, infant suckling
[21-23]. Suckling appears to trigger the release of var-
ious hormones responsible for regulation of digestion;
these hormones can alter rates of processes such as
gastric emptying [21]. Therefore, it is plausible that the
erratic AS absorption patterns observed for the post-
partum subjects in this study may have resulted from
the effects of lactation and recent infant suckling on
AS absorption.
The only significant covariate identified in the present
analysis was the effect of pregnancy on the clearance of
DHA; this effect was estimated to produce a 42.3% (95%
CI: 19.7% - 72.3%) proportional increase in DHA clear-
ance in pregnant women as compared to non-pregnant
controls. Clearance did not appear to differ substantially
between the two windows of pregnancy, but more sub-
jects in each trimester would likely be required for a dif-
ference between trimesters to be reliably detected.
Apparent DHA clearance values for pregnancy and con-
trol subjects in the present analysis are similar to those
obtained by non-compartmental methods, although
apparent DHA volume of distribution was somewhat
lower in the population, as compared to the non-com-
partmental, analysis [7]. In the present analysis, the
apparent volume of distribution of DHA trended higher
for pregnant subjects, but the association between preg-
nancy status and increased volume of distribution did
not meet the statistical significance criteria (p < 0.001)
for the described covariate analysis methods. However,
given that this association was statistically significant in
the initial step of covariate modelling, the association
would likely attain significance if assessed in a larger
number of subjects.
Figure 4 Goodness-of-fit plots for DHA. Dotted lines are smoothing lines. Solid lines are lines of identity.
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The source of the pregnancy-related accelerated DHA
clearance identified in this analysis is difficult to deter-
mine, as pharmacokinetic changes resulting from the
physiological changes of pregnancy are not presently
well understood. As DHA is metabolized through hepa-
tic glucuronidation by UGT1A9 and UGT2B7 [12],
induction of these enzymes could result in accelerated
DHA clearance. Induction of hepatic glucuronidation,
potentially by elevated sex hormone levels in pregnancy,
may be responsible for the substantial pregnancy-related
increases in glucuronidation observed for various drugs,
including lamotrigine [24,25], oxcarbazepine [26], and
lorazepam [27]. Alterations in hepatic blood flow could
also produce changes in DHA clearance. Although such
alterations in blood flow during pregnancy have been
investigated, the results of these investigations are not in
agreement [28]. Additionally, blood flow changes may
not be consistent across trimesters [29]. Therefore, the
manner in which hepatic blood flow alterations would
be expected to contribute to pregnancy-associated DHA
pharmacokinetic changes is difficult to predict.
The results of the present analysis are comparable to
those of McGready et al. They assessed DHA pharma-
cokinetics following oral AS administration to 24 preg-
nant women (2nd or 3rd trimester) of the Karen ethnic
group in Thailand with acute uncomplicated falciparum
malaria [5]. In their study, patients received a three-day
regimen of orally administered AS (4 mg/kg/day) with
250 mg atovaquone and 100 mg proguanil; medications
were given once daily with high fat milk. Samples used
for pharmacokinetic analysis were obtained prior to the
third daily dose and at seven time points between 0.5
and 12 hours following that dose. Since AS was detect-
able in only 21 of 323 samples, the investigators limited
their analysis to DHA. Using population pharmacoki-
netic analysis, they modelled DHA data using a one-
compartment model with a first-order rate of formation
modelled as a fixed effect. The parameter estimates they
obtained, adjusted for the median weight of their sub-
jects (50 kg), were 88.5 L/hr [95% CI 60 - 117 L/h] for
oral DHA clearance and 231.5 L [95% CI 57 - 406 L]
for DHA volume of distribution. Their estimate for
DHA clearance in pregnant patients is similar to the
estimate in the present analysis (91 L/h). The volume of
distribution estimate from the present analysis (91.4 L)
is lower than found by these investigators. However,
both the 91.4 L estimate and the 95% bootstrap confi-
dence interval for that estimate (78.5-109 L), fall within
their 95% confidence interval. Additionally, the 91.4 L
estimate is similar to that obtained by other analysts,
albeit obtained from the study of exclusively non-preg-
nant patients. Specifically, Teja-Isavadharm et al con-
ducted non-compartmental analysis of DHA kinetics
following oral AS administration to patients with falci-
parum malaria; their estimate of 1.33 L/kg [range: 0.70 -
2.70 L/kg] [30] is similar to the estimate obtained in the
current analysis, adjusted for the median weight of the
pregnancy and control groups, of 1.58 L/kg. A similar
Figure 5 Plot of visual predictive checks for AS and DHA. Open circles represent observed AS and DHA concentrations. The solid line
represents the median of the simulated concentrations. The dashed lines represent the 5th and 95th percentiles. The shaded areas represent the
95% confidence intervals for the prediction lines.
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estimate of 1.33 L/kg [95% CI 1.02 - 1.64] was obtained
by Newton et al when examining the kinetics of DHA
following oral AS administration to acute falciparum
malaria patients [31].
The pregnant women included in the present study
were asymptomatic, displayed low-grade parasitaemia,
and were otherwise generally healthy. Therefore, the
results from this study can be generalized to populations
for which intermittent preventative treatment regimens
are indicated. Given that the model was not constructed
using data from pregnant women with acute sympto-
matic malaria, it is not known if the model would opti-
mally describe AS and DHA pharmacokinetics in such
patients. However, given the findings of McGready et al,
it seems probable that the significant pregnancy-asso-
ciated increase in DHA oral clearance identified in the
present analysis would be observed in pregnant women
with acute malaria. In these patients, lower DHA blood
levels resulting from accelerated DHA clearance could
translate into reduced efficacy of AS and related com-
pounds. Lower levels could also select for survival of
parasites more tolerant to these compounds, increasing
the risk of resistance development.
Conclusions
In summary, this analysis describes a stable, predictive
population pharmacokinetic model for AS and DHA in
pregnant and non-pregnant women in the DRC. A cen-
tral finding of this analysis is that an increase in DHA
oral clearance is associated with pregnancy. The pre-
vious non-compartmental analysis of the data modelled
in the present study found a similar difference between
pregnant and non-pregnant women, but no statistically
significant difference between pregnant women and the
same women postpartum. However, given that the post-
partum data were highly variable, the results presented
here provide further support for the possibility that
pregnant patients would need to receive a higher dose
of AS in order to achieve equivalent DHA blood levels
as obtained by non-pregnant patients receiving the stan-
dard adult dose. Although a larger study would be
required to definitively characterize the optimal AS dose
adjustments for pregnant patients, the substantial preg-
nancy-associated increase in DHA clearance described
in the present analysis underscores the need for such a
study.
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